- Home
- OCFT vs CLLS Comparison
OCFT vs CLLS Comparison
Compare OCFT & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCFT
- CLLS
- Stock Information
- Founded
- OCFT 2015
- CLLS 1999
- Country
- OCFT China
- CLLS France
- Employees
- OCFT N/A
- CLLS N/A
- Industry
- OCFT Computer Software: Programming Data Processing
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- OCFT Technology
- CLLS Health Care
- Exchange
- OCFT Nasdaq
- CLLS Nasdaq
- Market Cap
- OCFT 290.5M
- CLLS 299.0M
- IPO Year
- OCFT 2019
- CLLS 2007
- Fundamental
- Price
- OCFT $7.16
- CLLS $3.07
- Analyst Decision
- OCFT Hold
- CLLS Buy
- Analyst Count
- OCFT 1
- CLLS 1
- Target Price
- OCFT $7.98
- CLLS $4.00
- AVG Volume (30 Days)
- OCFT 23.9K
- CLLS 76.4K
- Earning Date
- OCFT 11-13-2025
- CLLS 11-03-2025
- Dividend Yield
- OCFT N/A
- CLLS N/A
- EPS Growth
- OCFT N/A
- CLLS N/A
- EPS
- OCFT N/A
- CLLS N/A
- Revenue
- OCFT $228,020,185.00
- CLLS $63,438,000.00
- Revenue This Year
- OCFT N/A
- CLLS N/A
- Revenue Next Year
- OCFT $6.37
- CLLS $66.76
- P/E Ratio
- OCFT N/A
- CLLS N/A
- Revenue Growth
- OCFT N/A
- CLLS 223.09
- 52 Week Low
- OCFT $1.12
- CLLS $1.10
- 52 Week High
- OCFT $7.64
- CLLS $3.35
- Technical
- Relative Strength Index (RSI)
- OCFT 42.34
- CLLS 64.43
- Support Level
- OCFT $7.06
- CLLS $2.88
- Resistance Level
- OCFT $7.35
- CLLS $3.20
- Average True Range (ATR)
- OCFT 0.16
- CLLS 0.17
- MACD
- OCFT -0.00
- CLLS 0.03
- Stochastic Oscillator
- OCFT 33.33
- CLLS 73.53
About OCFT OneConnect Financial Technology Co. Ltd.
OneConnect Financial Technology Co Ltd is a technology-as-a-service provider for the financial services industry. It integrates extensive expertise in the industry with market technology to provide technology applications and technology-enabled business services to financial institutions. The integrated solutions and platforms it provides include digital banking solutions, digital insurance solutions, and the Gamma Platform, a technology infrastructure platform for financial institutions. Geographically, the company generates substantially all of its revenue from its business in the People's Republic of China (PRC).
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.